Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.57 |
| ▸ | HTR2C | P28335 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582713 | 0.90 | MCHR1 (0.68) | MCHR1MAPTKDM4E | |
| SCHEMBL5582632 | 0.89 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL5582768 | 0.81 | MCHR1 (0.68) | MCHR1HTR2C | |
| SCHEMBL5582558 | 0.81 | MCHR1 (0.66) | MCHR1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL5583028 | 0.81 | MCHR1 (0.68) | MCHR1HTR2CSMN1; SMN2RAB9A | |
| SCHEMBL5583048 | 0.80 | MCHR1 (0.69) | MCHR1HTR2CSMN1; SMN2RAB9A | |
| SCHEMBL5934692 | 0.80 | RAB9A (0.71) | MCHR1HTR2CSMN1; SMN2MAPTRAB9A | |
| SCHEMBL5582628 | 0.80 | KCNH2 (0.56) | MCHR1MAPTRAB9AKDM4EKMT2A | |
| SCHEMBL5582656 | 0.80 | MCHR1 (0.69) | MCHR1HTR2CSMN1; SMN2RAB9A | |
| SCHEMBL5582869 | 0.78 | MCHR1 (0.81) | MCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885SMN1; SMN2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.